MedTrace Logo

Transbronchial vs Transthoracic Ablation for Early-stage Peripheral Lung Cancer

NCT06052098 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2023-12-06

No results posted yet for this study

Summary

The purpose of this study is to investigate the efficacy and safety of RFA through a transthoracic or transbronchial approach in the treatment of early-stage peripheral lung cancer.

Conditions

  • Stage IA Lung Cancer

Interventions

DEVICE

The disposable pulmonary radiofrequency ablation catheter and pulmonary radiofrequency ablation system

Procedure: In combination with guided bronchoscopy and CBCT, the ablation catheter is placed in the target lesion. CBCT confirms the tool in the lesion, adjusts the position of the ablation catheter, and monitors the extent of ablation.

DEVICE

The disposable percutaneous radiofrequency ablation needle and pulmonary radiofrequency ablation system

Procedure: The ablation needle is punctured into the lesion under CT guidance. The extent of the ablation is monitored by CT.

Sponsors & Collaborators

  • Shanghai Chest Hospital

    collaborator OTHER

  • Hangzhou Broncus Medical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Jiayuan Sun, MD, PhD · Shanghai Chest Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-11
Primary Completion
2025-04-30
Completion
2027-10-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06052098 on ClinicalTrials.gov